Li Jia, Merl Man Yee, Chabot John, Saif Muhammad Wasif
Yale University School of Medicine, New Haven, CT, USA.
JOP. 2010 Jul 5;11(4):310-2.
Pancreatic cancer represents the 4th leading cause of cancer deaths in the United States. Surgical resection remains the only potential curative approach. Current standard adjuvant therapy is gemcitabine monotherapy for 6 months. This year several trials investigated other combinations with or without molecular target agents, with or without concurrent radiation attempting to optimize adjuvant therapy. Several abstracts presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting are highlighted here and will be further discussed in this review article. Abstracts #4012, #4059, and TPS226 added immunotherapy to adjuvant treatment. Abstract #4034 demonstrated lack of efficacy by adding either cetuximab or bevacizumab to known adjuvant therapies. Abstract e14625 combined S-1 to gemcitabine and abstract #4113 demonstrated a positive correlation between symptoms and CA 19-9 levels with the length of survival.
胰腺癌是美国癌症死亡的第四大主要原因。手术切除仍然是唯一可能的治愈方法。目前的标准辅助治疗是吉西他滨单药治疗6个月。今年，多项试验研究了其他联合治疗方案，包括是否联合分子靶向药物、是否联合同期放疗，试图优化辅助治疗。本文重点介绍了在2010年美国临床肿瘤学会（ASCO）年会上发表的几篇摘要，并将在这篇综述文章中进一步讨论。摘要#4012、#4059和TPS226在辅助治疗中加入了免疫治疗。摘要#4034表明，在已知的辅助治疗中加入西妥昔单抗或贝伐单抗均无效。摘要e14625将S-1与吉西他滨联合使用，摘要#4113表明症状与CA 19-9水平之间以及生存期之间呈正相关。
